Citations

Clear

3042 citation(s) found for "Kumar, S".

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States
Costa, Luciano J. , Brill, Ilene , Omel, James, Godby, Kelly, Kumar, Shaji , Brown, Elizabeth E. , Costa, Luciano J

Mayo Clinic

Blood Advances | January 5, 2017 | Volume: 1 | Issue: 4 | Pages: 282-287

10.1182/bloodadvances.2016002493 | PMID 29296944 Get It

Key PointsIncidence of MM has increased in recent years in the United States with a tendency for younger age at diagnosis. Five- and 10-year survival of MM patients is improving among racial/ethnic minorities, but remains limited in patients ≥75 years of age.
SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT
Chhablani, Jay , Dedhia, Chintan , Peguda, Hari Kumar , Stewart, Michael, group, on behalf of Ziv-aflibercept study, group, on behalf of Ziv-aflibercept study

Mayo Clinic

Retina | January 4, 2017 | Volume: 37 | Issue: 10 | Pages: 1859-1865

10.1097/iae.0000000000001440 | PMID 28060148 Get It

Purpose: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). Methods: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30. Primary outcome measures consisted of safety assessments (signs of clinical toxicity and electroretinographic abnormalities). Secondary outcome measures included changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) of the macula. Results: Twenty-one eyes of 20 patients (12 males) received injections. Etiologies responsible for the choroidal neovascular membranes included age-related macular degeneration (14), polypoidal choroidal vasculopathy (PCV) (3), myopia (2), and idiopathic juxtafoveal telangiectasia (2). None of the patients complained of worsening vision or pain after the intravitreal injections and no intraocular inflammation was seen. No significant changes in the electroretinographic b/a ratio from baseline to 1 month were measured (scotopic: P = 0.89; photopic: P = 0.13) and mean intraocular pressures were unchanged (14.2 ± 3.6 vs. 13.7 ± 3.0 mmHg; P = 0.62). Mean best-corrected visual acuity did not change significantly from baseline to 1 month (0.66 ± 0.37 logMAR [Snellen equivalent: 20/100] vs. 0.61 ± 0.35 logMAR [Snellen equivalent: 20/80]; P = 0.72) but significant improvements in central subfield thickness were seen (343 ± 177 vs. 210 ± 133 μ m; P = 0.01). Conclusion: Single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL) appear to be safe through 1 month.
Genetic variation at 16q24.2 is associated with small vessel stroke
Traylor, Matthew , Nalls, Mike A., Cotlarciuc, Ioana, Radmanesh, Farid , Hanscombe, Ken B. , Langefeld, Carl D. , Saleheen, Danish , Rost, Natalia S. , Yet, İdil , Spector, Tim D. , Bell, Jordana T. , Hannon, Eilís , Mill, Jonathan , Chauhan, Ganesh , Debette, Stéphanie , Bis, Joshua C. , Longstreth, W.T. , Seshadri, Sudha , Hamilton‐Bruce, Monica Anne , Jiménez-Conde, Jordi , Schmidt, Reinhold, Słowik, Agnieszka , Lemmens, Robin , Lindgren, Arne, Melander, Olle , Grewal, Raji P., Sacco, Ralph L., Rexrode, Kathryn M. , Arnett, Donna K. , Johnson, Julie A. , Benavente, Oscar, Wasssertheil‐Smoller, Sylvia, Lee, Jin‐Moo , Pulit, Sara L. , Wong, Quenna , Rich, Stephen S. , Bakker, Paul I. W. de , McArdle, Patrick F. , Woo, Daniel , Anderson, Christopher D. , Xu, Huichun , Heitsch, Laura , Fornage, Myriam , Stefansson, Kari, Þorsteinsdóttir, Unnur , Grétarsdóttir, Sólveig , Lewis, Cathryn M. , Sudlow, Cathie , Rothwell, Peter M. , Boncoraglio, Giorgio B. , Thijs, Vincent , Levi, Christopher , Kittner, Steven J. , Dichgans, Martin , Worrall, Bradford B. , Markus, Hugh S. , Malik, Rainer , Þorleifsson, Guðmar , Ikram, M. Arfan , Launer, Lenore J. , Cole, John W. , Lindgren, Arne, Rundek, Tatjana , Jern, Christina , Stefansson, Kari, Lewis, Cathryn M , Sharma, Pankaj Kumar , Meschia, James F. , Rosand, Jonathan M. , Mitchell, Braxton D. , Dichgans, Martin , Rich, Stephen S , Seshadri, Sudha , Debette, Stephanie , Lemmens, Robin , Arnett, Donna K , Lee, Jin-Moo

Mayo Clinic

Annals of Neurology | December 20, 2016 | Volume: 81 | Issue: 3 | Pages: 383-394

10.1002/ana.24840 | PMID 27997041 Get It

Objective Genome‐wide association studies (GWAS) have been successful at identifying associations with stroke and stroke subtypes, but have not yet identified any associations solely with small vessel stroke (SVS). SVS comprises one quarter of all ischemic stroke and is a major manifestation of cerebral small vessel disease, the primary cause of vascular cognitive impairment. Studies across neurological traits have shown that younger‐onset cases have an increased genetic burden. We leveraged this increased genetic burden by performing an age‐at‐onset informed GWAS meta‐analysis, including a large younger‐onset SVS population, to identify novel associations with stroke. Methods We used a three‐stage age‐at‐onset informed GWAS to identify novel genetic variants associated with stroke. On identifying a novel locus associated with SVS, we assessed its influence on other small vessel disease phenotypes, as well as on messenger RNA (mRNA) expression of nearby genes, and on DNA methylation of nearby CpG sites in whole blood and in the fetal brain. Results We identified an association with SVS in 4,203 cases and 50,728 controls on chromosome 16q24.2 (odds ratio [OR; 95% confidence interval {CI}] = 1.16 [1.10–1.22]; p = 3.2 × 10 −9 ). The lead single‐nucleotide polymorphism (rs12445022) was also associated with cerebral white matter hyperintensities (OR [95% CI] = 1.10 [1.05–1.16]; p = 5.3 × 10 −5 ; N = 3,670), but not intracerebral hemorrhage (OR [95% CI] = 0.97 [0.84–1.12]; p = 0.71; 1,545 cases, 1,481 controls). rs12445022 is associated with mRNA expression of ZCCHC14 in arterial tissues ( p = 9.4 × 10 −7 ) and DNA methylation at probe cg16596957 in whole blood ( p = 5.3 × 10 −6 ). Interpretation 16q24.2 is associated with SVS. Associations of the locus with expression of ZCCHC14 and DNA methylation suggest the locus acts through changes to regulatory elements. Ann Neurol 2017;81:383–394
SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function
Li, Man , Weeks, Olivia , Mijatovic, Vladan, Teumer, Alexander , Tromp, Gerard , Fuchsberger, Christian , Gorski, Mathias , Nutile, Teresa , Sedaghat, Sanaz , Sorice, Rossella , Arking, Dan E. , Bihlmeyer, Nathan A. , Böger, Carsten A., Carroll, Robert J. , Cornelis, Marilyn C., Faul, Jessica D. , Feitosa, Mary F. , Gambaro, Giovanni , Gasparini, Paolo , Giulianini, Franco, Heid, Iris M. , Huang, Jinyan , Imboden, Medea , Jeff, Janina M., Jhun, Min A., Katz, Ronit , Kifley, Annette , Kilpeläinen, Tuomas O. , Laakso, Markku , Li‐Gao, Ruifang , Lohman, Kurt, Lu, Yingchang , Mägi, Reedik , Mihailov, Evelin, Mohlke, Karen L. , Mook‐Kanamori, Dennis O. , Robino, Antonietta , Salvi, Erika , Schick, Ursula M., Schulz, Christina‐Alexandra , Smith, Albert V. , Traglia, Michela , Yerges-Armstrong, Laura M. , Goodarzi, Mark O. , Kraja, Aldi T., Wessel, Jennifer , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Boerwinkle, Eric , Borecki, Ingrid B. , Bork‐Jensen, Jette , Böttinger, Erwin P. , Braga, Daniele , Brandslund, Ivan , Brody, Jennifer A. , Carey, David J. , Christensen, Cramer, Crook, Errol D., Boer, Ian H. de , Vries, Aiko P. J. de , Devuyst, Olivier , Dreisbach, Albert W. , Endlich, Karlhans , Franco, Oscar H. , Glümer, Charlotte , Gottesman, Omri, Grarup, Niels , Guðnason, Vilmundur , Harris, Tamara B., Hofman, Albert , Husemoen, Lise Lotte N. , Jackson, Rebecca D. , Jørgensen, Marit E. , Kähönen, Mika , Kardia, Sharon L. R., König, Wolfgang , Kriebel, Jennifer , Lauritzen, Torsten , Lehtimäki, Terho , Levy, Daniel , Linksted, Pamela , Loos, Ruth J. F. , Lupo, Antonio , Meisinger, Christine, Melander, Olle , Mitchell, Paul, Nauck, Matthias, Orho‐Melander, Marju , Parsa, Afshin, Pedersen, Oluf , Peters, Annette , Peters, Ulrike , Polašek, Ozren , Qi, Lu , Reiner, Alex P. , Rettig, Rainer, Ridker, Paul M., Rivadeneira, Fernando , Rossouw, Jacques E. , Schmidt, Frank , Soranzo, Nicole , Strauch, Konstantin , Toniolo, Daniela , Uitterlinden, André G. , Ulivi, Sheila , Velayutham, Dinesh , Völker, Uwe , Völzke, Henry , Waldenberger, Mélanie , Wang, Jie Jin , Weir, David R. , Witte, Daniel R. , Kuivaniemi, Helena , Fox, Caroline S., Franceschini, Nora , Goessling, Wolfram , Köttgen, Anna , Chu, Audrey Y., Rudan, Igor , Vasan, Ramachandran S. , Duijn, Cornelia M. van , Zhao, Wei , Padmanabhan, Sandosh , Lindgren, Cecilia M. , Franks, Paul W. , Weiß, Stefan , Langenberg, Claudia , Hattersley, Andrew T. , Turner, Stephen T. , Li, Yong , Huffman, Jennifer E. , Lyytikäinen, Leo‐Pekka , Tin, Adrienne , Yang, Qiong , Ahluwalia, Tarunveer S. , Chasman, Daniel I. , Dehghan, Abbas , Jackson, Anne , Kumar, Ashish , Malerba, Giovanni , Ruderfer, Douglas , Smith, Jennifer A. , Zhao, Wei , Liu, Chunyu , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Campbell, Archie I , Coresh, Josef , Curhan, Gary C. , Cusi, Daniele , Denny, Joshua C. , Esko, Tõnu , Fülöp, Tibor , Gerhard, Glenn S. , Hansen, Torben , Hayward, Caroline , Hocking, Lynne J. , Hu, Frank B. , Jørgensen, Torben , Kooperberg, Charles , Launer, Lenore J. , Linneberg, Allan , Liu, Ching‐Ti , Meisinger, Christine, Metspalu, Andres , Nürnberg, Peter , Porteous, David John , Probst-Hensch, Nicole M , Psaty, Bruce M. , Raitakari, Olli Tuomas , Siscovick, David S. , Weiss, Stefan , Völker, Uwe , Teumer, Alexander , van Duijn, Cornelia M , Vasan, Ramachandran S , Smith, Albert V , Loos, Ruth J F , Li-Gao, Ruifang , Brody, Jennifer A , Padmanabhan, Sandosh , Levy, Daniel , de Vries, Aiko P J , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Journal of the American Society of Nephrology | December 5, 2016 | Volume: 28 | Issue: 3 | Pages: 981-994

10.1681/asn.2016020131 | PMID 27920155 Get It

Genome-wide association studies have identified >50 common variants associated with kidney function, but these variants do not fully explain the variation in eGFR. We performed a two-stage meta-analysis of associations between genotypes from the Illumina exome array and eGFR on the basis of serum creatinine (eGFRcrea) among participants of European ancestry from the CKDGen Consortium ( n Stage1 : 111,666; n Stage2 : 48,343). In single-variant analyses, we identified single nucleotide polymorphisms at seven new loci associated with eGFRcrea ( PPM1J , EDEM3, ACP1, SPEG, EYA4, CYP1A1 , and ATXN2L ; P Stage1 <3.7×10 −7 ), of which most were common and annotated as nonsynonymous variants. Gene-based analysis identified associations of functional rare variants in three genes with eGFRcrea, including a novel association with the SOS Ras/Rho guanine nucleotide exchange factor 2 gene, SOS2 ( P =5.4×10 −8 by sequence kernel association test). Experimental follow-up in zebrafish embryos revealed changes in glomerular gene expression and renal tubule morphology in the embryonic kidney of acp1- and sos2 -knockdowns. These developmental abnormalities associated with altered blood clearance rate and heightened prevalence of edema. This study expands the number of loci associated with kidney function and identifies novel genes with potential roles in kidney formation.
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine
Frontera, Jennifer , Lewin, John J. , Aisiku, Imo, Alexandrov, Anne W. , Cook, Aaron M. , Zoppo, Gregory J. del, Kumar, Monisha A. , Stiefel, Michael , Teitelbaum, Jeanne , Wartenberg, Katja E. , Zerfoss, Cindy, Frontera, Jennifer A, Rabinstein, Alejandro A. , Aisiku, Imoigele P. , Peerschke, Ellinor I.B. , Cook, Aaron M , Frontera, Jennifer

Mayo Clinic

Critical Care Medicine | November 18, 2016 | Volume: 44 | Issue: 12 | Pages: 2251-2257

10.1097/ccm.0000000000002057 | PMID 27858808 Get It

Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors
Jouni, Hayan, Aubry, Mary C., Lacy, Martha Q. , Kumar, Shaji , Frye, Robert L. , Herrmann, Joerg , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | November 17, 2016 | Volume: 92 | Issue: 2 | Pages: 220-221

10.1002/ajh.24608 | PMID 27859518 Get It

Late outcomes of adult survivors of childhood non‐Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study
Ehrhardt, Matthew J. , Sandlund, John T., Zhang, Nan , Liu, Wei , Ness, Kirsten K. , Bhakta, Nickhill , Chemaitilly, Wassim , Krull, Kevin R. , Brinkman, Tara M. , Crom, Deborah B., Kun, Larry E. , Kaste, Sue C. , Armstrong, Gregory T. , Srivastava, Kumar , Mulrooney, Daniel A. , Green, Daniel M. , Robison, Leslie L. , Hudson, Melissa M. , Mulrooney, Daniel A , Ness, Kirsten K , Bhakta, Nickhill

Mayo Clinic

Pediatric Blood & Cancer | November 16, 2016 | Volume: 64 | Issue: 6 | Pages: No page available

10.1002/pbc.26338 | PMID 27860222 Get It

AbstractBackgroundSurvivors of childhood non‐Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically evaluated cohort of 200 childhood NHL survivors.MethodChronic health and neurocognitive conditions were graded as per a modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and impaired physical function defined as performance < 10th percentile of normative data. Multivariable regression was used to investigate associations between sociodemographic characteristics, therapeutic exposures, and outcomes.ResultsSurvivors were a median age of 10 years (range 1–19) at diagnosis and 34 years (range 20–58) at evaluation. Eighty‐eight (44%) received radiation, 46 (23%) cranial radiation, and 69 (35%) high‐dose methotrexate. Most prevalent CTCAE Grades 3–4 (severe life‐threatening) conditions were obesity (35%), hypertension (9%), and impairment of executive function (13%), attention (9%), and memory (4%). Many had impaired strength (48%), flexibility (39%), muscular endurance (36%), and mobility (36%). Demographic and treatment‐related factors were associated with the development of individual chronic diseases and functional deficits.ConclusionsClinical evaluation identified a high prevalence of chronic health conditions, neurocognitive deficits, and performance limitations in childhood NHL survivors.
Immune Therapies in Multiple Myeloma
Kumar, Shaji , Anderson, Kenneth C.

Mayo Clinic

Clinical Cancer Research | November 15, 2016 | Volume: 22 | Issue: 22 | Pages: 5453-5460

10.1158/1078-0432.ccr-16-0868 | PMID 28151713 Get It

Abstract Treatment paradigms have changed rapidly for multiple myeloma, and immune therapies have taken center stage. Advances in therapies for myeloma have led to a dramatic improvement in the survival of patients with this incurable malignancy. The immune system is significantly impaired in patients with myeloma as a result of the disease leading to suppression of normal plasma cells as well the negative effects on cellular immunity. Given this scenario, immune approaches have not been successful until recently. Monoclonal antibodies directed against CD38 (daratumumab) and SLAMF7 (elotuzumab) are already in the clinic, and several other antibodies directed against different plasma cell antigens are under evaluation. Although immune checkpoint inhibition with PD-1 inhibitors had no clinical efficacy when the inhibitors were used as single agents, it has led to some dramatic results when the inhibitors are combined with immunomodulatory drugs such as lenalidomide and pomalidomide. Vaccination strategies have shown in vivo immune responses but no clear clinical efficacy. Newer approaches to vaccination with multiple antigens, used in combinations with immunomodulatory drugs and in the setting of minimal residual disease, have all increased possibility of this approach succeeding. Ex vivo effector cell expansion also appears to be promising and is in clinical trials. Finally, a chimeric antigen receptor T-cell approach appears to have some promise based on isolated reports of success and remains an area of intense investigation. Immune-based approaches can potentially augment or even supplant some of the current approaches and, given the low toxicity profile, may hold great potential in the early treatment of precursor-stage diseases. Clin Cancer Res; 22(22); 5453–60. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”
Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial
Kaizer, Alexander , Rudser, Kyle , Nathan, Brandon M. , Gross, Amy C. , Sunni, Muna , Abuzzahab, M. Jennifer, Schwartz, Betsy L., Kumar, Seema , Petryk, Anna , Ryder, Justin R. , Kelly, Aaron S. , Fox, Claudia K. , Billington, Charles J. , Fox, C K , Ryder, J R , Kaizer, Alexander M , Kelly, Aaron S

Mayo Clinic

Obesity | November 3, 2016 | Volume: 24 | Issue: 12 | Pages: 2553-2561

10.1002/oby.21633 | PMID 27807925 Get It

ObjectiveTo assess the safety and efficacy of short‐term meal replacement therapy followed by topiramate for body mass index (BMI) reduction in adolescents with severe obesity.MethodsAdolescents (ages 12–18 years) with severe obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m2) were recruited for this double‐blind, randomized, placebo‐controlled trial. Participants completed 4 weeks of meal replacement therapy followed by randomization (1:1) to either 24 weeks of topiramate 75 mg/day or placebo. Mean changes were compared between groups.ResultsThirty adolescents (mean age 15.2 ± 1.7 years, mean BMI 40.3 ± 4.6 kg/m2) completed the meal replacement phase and were randomized; 21 completed the study. The difference in mean percent change in BMI between the topiramate and placebo groups was not significant (−1.9%; 95% CI: −5.2% to +1.5%; P = 0.291). Significant improvements in visceral fat and very‐low‐density lipoprotein cholesterol were observed in the topiramate compared with the placebo group. There were no concerning changes in neurocognitive function or bone health.ConclusionsIn this pilot study, 4 weeks of meal replacement therapy followed by 24 weeks of low‐dose topiramate compared with meal replacement therapy alone did not result in significant BMI reduction for adolescents with severe obesity.
Multi‐institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors
Shostrom, Valerie , Kumar, Sameera , Zhen, Weining, Hallemeier, Christopher L. , Holland, John , Harkenrider, Matthew M. , Iskhanian, Adrian S., Neboori, Hanmanth J., Attia, Albert, Lee, Percy , Alite, Fiori , Walker, Joshua M. , Stahl, John M. , Wang, Kyle , Bingham, Brian , Hadzitheodorou, C., Decker, Roy H. , McGarry, Ronald C., Simone, Charles B. , Verma, Vivek , Hallemeier, Christopher Leigh , Braunstein, Steve , Jabbour, Salma K , Simone, Charles B

Mayo Clinic

Cancer | October 14, 2016 | Volume: 123 | Issue: 4 | Pages: 688-696

10.1002/cncr.30375 | PMID 27741355 Get It

BACKGROUNDStereotactic body radiotherapy (SBRT) is the standard of care for patients with nonoperative, early‐stage non–small cell lung cancer (NSCLC) measuring < 5 cm, but its use among patients with tumors measuring ≥5 cm is considerably less defined, with the existing literature limited to small, single‐institution reports. The current multi‐institutional study reported outcomes evaluating the largest such population reported to date.METHODSClinical/treatment characteristics, outcomes, toxicities, and patterns of failure were assessed in patients with primary NSCLC measuring ≥5 cm without evidence of distant/lymph node metastasis who underwent SBRT using ≤5 fractions. Statistics included Kaplan‐Meier survival analyses and univariate/multivariate Cox proportional hazards models.RESULTSA total of 92 patients treated from 2004 through 2016 were analyzed from 12 institutions. The median follow‐up was 12 months (15 months in survivors). The median age and tumor size among the patients were 73 years (range, 50‐95 years) and 5.4 cm (range, 5.0‐7.5 cm), respectively. The median dose/fractionation was 50 Gray/5 fractions. The actuarial local control rates at 1 year and 2 years were 95.7% and 73.2%, respectively. The disease‐free survival rate was 72.1% and 53.5%, respectively, at 1 year and 2 years. The 1‐year and 2‐year disease‐specific survival rates were 95.5% and 78.6%, respectively. The median, 1‐year, and 2‐year overall survival rates were 21.4 months, 76.2%, and 46.4%, respectively. On multivariate analysis, lung cancer history and pre‐SBRT positron emission tomography maximum standardized uptake value were found to be associated with overall survival. Posttreatment failures were most commonly distant (33% of all disease recurrences), followed by local (26%) and those occurring elsewhere in the lung (23%). Three patients had isolated local failures. Grade 3 to 4 toxicities included 1 case (1%) and 4 cases (4%) of grade 3 dermatitis and radiation pneumonitis, respectively (toxicities were graded according to the Common Terminology Criteria for Adverse Events [version 4.0]). Grades 2 to 5 radiation pneumonitis occurred in 11% of patients. One patient with a tumor measuring 7.5 cm and a smoking history of 150 pack‐years died of radiation pneumonitis.CONCLUSIONSThe results of the current study, which is the largest study of patients with NSCLC measuring ≥5 cm reported to date, indicate that SBRT is a safe and efficacious option. Cancer 2017;123:688–696. © 2016 American Cancer Society.